Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,018 public trials 2,029 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL)

NCT02185781

Conditions
Acute Lymphoblastic Leukemia, Complete Hematologic Remission (CHR), Hematologic Diseases, +15 more
Locations
  • ISS/AIFA Roma, Italy
  • Ospedale S. Eugenio Roma, Italy
  • Università Cattolica del Sacro Cuore - Policlinico A. Gemelli Roma, Italy
  • Università degli Studi "Sapienza" - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia Roma, Italy
View Trial Details
Completed

A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

NCT03886831

Conditions
Adenocarcinoma, Adenoid Cystic Carcinoma, Anemia, +39 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • UCSF Precision Cancer Medicine Building San Francisco, California, United States
  • Christiana Care Health Services, Christiana Hospital Newark, Delaware, United States
  • Florida Cancer Specialists Lake Mary, Florida, United States
View all 23 locations
View Trial Details
Completed

An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma

NCT02726581

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Local Institution - 0020 Birmingham, Alabama, United States
  • Local Institution - 0160 Mobile, Alabama, United States
  • Local Institution - 0163 Fayetteville, Arkansas, United States
  • Local Institution - 0118 Bakersfield, California, United States
View all 121 locations
View Trial Details
Completed

A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

NCT02061761

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +19 more
Locations
  • Local Institution - 0007 Baltimore, Maryland, United States
  • Local Institution - 0004 Boston, Massachusetts, United States
  • Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States
  • Local Institution - 0010 St Louis, Missouri, United States
View Trial Details

Related conditions